Janus kinase inhibitors in immunoinflammatory rheumatic diseases
- 作者: Nasonov E.1,2
-
隶属关系:
- Nasonova Research Institute of Rheumatology
- Sechenov First Moscow State Medical University (Sechenov University)
- 期: 卷 94, 编号 5 (2022)
- 页面: 605-609
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/108773
- DOI: https://doi.org/10.26442/00403660.2022.05.201501
- ID: 108773
如何引用文章
全文:
详细
Despite great advances in the diagnosis and treatment of immunoinflammatory rheumatic diseases, which have led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology – the restoration of the quality of life and the reduction of mortality to the population level – are far from being resolved. This served as a stimulus for the study of new approaches to the pharmacotherapy of IVRD, one of which is associated with the use of low molecular weight chemically synthesized drugs that inhibit intracellular "signaling" molecules – Janus kinase. Modern advances regarding the use of Janus kinase inhibitors in the treatment of immunoinflammatory rheumatic diseases and COVID -19 are considered.
作者简介
Evgeny Nasonov
Nasonova Research Institute of Rheumatology; Sechenov First Moscow State Medical University (Sechenov University)
编辑信件的主要联系方式.
Email: nasonov@irramn.ru
ORCID iD: 0000-0002-1598-8360
акад. РАН, д-р мед. наук, проф., науч. рук. ФГБНУ «НИИ ревматологии им. В.А. Насоновой», зав. каф. ревматологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
俄罗斯联邦, Moscow; Moscow参考
- McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. doi: 10.1371/journal.pmed.0030297
- Szekanecz Z, McInnes IB, Schett G, et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-95. doi: 10.1038/s41584-021-00652-9
- Schett G, McInnes IB, Neurath MF. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. N Engl J Med. 2021;385(7):628-39. doi: 10.1056/NEJMra1909094
- Van Wesemael T, Huizinga TW, Toes REM, van der Woude D. From phenotype to pathophysiology – placing rheumatic diseases in an immunological perspective. Lancet Rheumatol. 2022;4(3):E166-7. doi: 10.1016/S2665-9913(21)00369-6
- Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
- Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Rheumatology Science and Practice. 2017;55(4):409-19 (in Russian)]. doi: 10.14412/1995-4484-2017-409-419
- Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases – past, present and future. Nat Rev Rheumatol. 2017;13(7):443-8. doi: 10.1038/nrrheum.2017.95
- Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201
- Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16 [Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Rheumatology Science and Practice. 2019;57(1):8-16 (in Russian)]. doi: 10.14412/1995-4484-2019-8-16
- Spinelli FR, Meylan F, O'Shea JJ, Gadina M. JAK inhibitors: Ten years after. Eur J Immunol. 2021;51(7):1615-27. doi: 10.1002/eji.202048922
- Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133-45. doi: 10.1038/s41584-021-00726-8
- Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317
- Насонов Е.Л., Авдеева А.С., Лила А.М. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть I). Научно-практическая ревматология. 2020;58(1):62-79 [Nasonov EL, Avdeeva AS, Lila AM. Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I). Rheumatology Science and Practice. 2020;58(1):62-79 (in Russian)]. doi: 10.14412/1995-4484-2020-62-79
- Насонов Е.Л., Авдеева А.С., Лила А.М. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть II). Научно-практическая ревматология. 2020;58(2):214-24 [Nasonov EL, Avdeeva AS, Lila AM. Efficacy and safety of tofacitinib for immunemediated inflammatory rheumatic diseases (Part II). Rheumatology Science and Practice. 2020;58(2):214-24 (in Russian)]. doi: 10.14412/1995-4484-2020-214-224
- Насонов Е.Л., Лила А.М. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2020;58(3):304-16 [Nasonov EL, Lila AM. Baricitinib: new pharmacotherapy options for rheumatoid arthritis and other immune-mediated inflammatory rheumatic diseases. Rheumatology Science and Practice. 2020;58(3):304-16 (in Russian)]. doi: 10.14412/1995-4484-2020-304-316
- Насонов Е.Л., Лила А.М. Перспективы применения упадацитиниба при ревматоидном артрите и других иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2020;58(5):532-43 [Nasonov EL, Lila AM. The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases. Rheumatology Science and Practice. 2020;58(5):532-43 (in Russian)]. doi: 10.47360/1995-4484-2020-532-543
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-99. doi: 10.1136/annrheumdis-2019-216655
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108-23. doi: 10.1002/art.41752
- Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159
- Nwaogu A, Bond A, Smith PJ. Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis – NICE guidance. Frontline Gastroenterol. 2020;12(2):133-6. doi: 10.1136/flgastro-2020-101502
- Kerschbaumer A, Smolen JS, Nash P, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. 2020;6(3):e001374. doi: 10.1136/rmdopen-2020-001374
- Campanaro F, Batticciotto A, Zaffaroni A, et al. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmun Rev. 2021;20(10):102902. doi: 10.1016/j.autrev.2021.102902
- Keeling S, Maksymowych WP. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Rev Clin Immunol. 2021;17(7):701-15. doi: 10.1080/1744666X.2021.1925541
- Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-43. doi: 10.1038/nrrheum.2017.23
- Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398
- Yates M, Mootoo A, Adas M, et al. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis. Arthritis Rheumatol. 2021;73(5):779-88. doi: 10.1002/art.41580
- Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316-26. doi: 10.1056/NEJMoa2109927
- Khosrow-Khavar F, Kim SC, Lee H, et al. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022:annrheumdis-2021-221915. doi: 10.1136/annrheumdis-2021-221915
- Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017;49:96-102. doi: 10.1016/j.coi.2017.09.003
- Насонов Е.Л., Авдеева А.С. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-61 [Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type i interferon: new evidence. Rheumatology Science and Practice. 2019;57(4):452-61 (in Russian)]. doi: 10.14412/1995-4484-2019-452-461
- Gómez-Arias PJ, Gómez-García F, Hernández-Parada J, et al. Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review. Dermatol Ther (Heidelb). 2021;11(3):733-50. doi: 10.1007/s13555-021-00517-9
- Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. doi: 10.1093/rheumatology/kew431
- Chapman S, Kwa M, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: Part I. A comprehensive review. J Am Acad Dermatol. 2022;86(2):406-13. doi: 10.1016/j.jaad.2021.07.002
- Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: Part II. A comprehensive review. J Am Acad Dermatol. 2022;86(2):414-22. doi: 10.1016/j.jaad.2021.06.873
- Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-32 [Nasonov EL. Coronavirus disease 2019 (COVID-19): a rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (in Russian)]. doi: 10.14412/1995-4484-2020-123-132
- Насонов ЕЛ. Коронавирусная болезни 2019 (COVID-19): вклад ревматологии. Терапевтический архив. 2021;93(5):537-50 [Nasonov EL. 2019 Coronavirus disease (COVID-19): contribution of rheumatology. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(5):537-50 (in Russian)]. doi: 10.2644/00403660.2021.05.200799
- Fajgenbaum DC, June CH, Cytokine Storm. N Engl J Med. 2020;383:2255-73. doi: 10.1056/NEJMra2026131
- Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259-68. doi: 10.1038/nrrheum.2015.179
- Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-44. doi: 10.1016/S2213-2600(20)30404-5
- Nissen CB, Sciascia S, de Andrade D, et al. The role of antirheumatics in patients with COVID-19. Lancet Rheumatol. 2021;3(6):e447-59. doi: 10.1016/S2665-9913(21)00062-X
- Stebbing J, Krishnan V, de Bono S, et al. Sacco Baricitinib Study Group. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020;12(8):e12697. doi: 10.15252/emmm.202012697
- Florescu DF, Kalil AC. Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19. Curr Opin Crit Care. 2021;27(5):493-6. doi: 10.1097/MCC.0000000000000869
- Fagni F, Simon D, Tascilar K, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021;3(10):e724-36. doi: 10.1016/S2665-9913(21)00247-2
- Насонов Е.Л., Лила А.М., Мазуров В.И., и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-54 [Nasonov EL, Lila AM, Mazurov VI, et al. Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Rheumatology Science and Practice. 2021;59(3):239-54 (in Russian)]. doi: 10.47360/1995-4484-2021-239-254
- Насонов Е.Л., Белов Б.С., Лила А.М., и др. Течение и исходы COVID-19 у пациентов с иммуновоспалительными ревматическими заболеваниями: предварительные данные регистра НИИР/АРР-COVID-19 и обзор литературы. Научно-практическая ревматология. 2021;59(6):666-75 [Nasonov EL, Belov BS, Lila AM, et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. Rheumatology Science and Practice. 2021;59(6):666-75 (in Russian)].
- Seror R, Camus M, Salmon JH, et al. Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. Lancet Rheumatol. 2022;4(1):e8-e11. doi: 10.1016/S2665-9913(21)00314-3
- Белов Б.С., Лила А.М., Насонов Е.Л. Вакцинация против SARS-CoV-2 при ревматических заболеваниях: вопросы безопасности. Научно-практическая ревматология. 2022;60(1):21-31 [Belov BS, Lila AM, Nasonov EL. Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. Rheumatology Science and Practice. 2022;60(1):21-31 (in Russian)]. doi: 10.47360/1995-4484-2022-21-31
- Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol. 2018;30(2):207-14. doi: 10.1097/BOR
- Mylonas A, Conrad C. Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Front Immunol. 2018;9:2746. doi: 10.3389/fimmu.2018.02746
- Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs. 2017;31(4):299-316. doi: 10.1007/s40259-017-0231-8